Uterine leiomyomas are the most common noncancerous neoplasms of the uterus affecting up to 80% of reproductive-age women.^[@R1],[@R2]^ They produce a variety of symptoms in about half of these women, the most common being heavy menstrual bleeding, which can lead to anemia.^[@R3]--[@R5]^ Leiomyomas can have a major effect on a woman\'s quality of life.^[@R6]--[@R11]^ Surgery has been the mainstay of leiomyoma treatment, with hysterectomy accounting for almost 70% of leiomyoma-related procedures.^[@R12],[@R13]^ Medical treatment, consisting of oral contraceptives, progestins, tranexamic acid, and gonadotropin-releasing hormone agonists (ie, leuprolide acetate) are often used to provide symptomatic relief; most of which are limited to short-term efficacy.^[@R14]--[@R16]^ There is a clinical unmet need for an approved long-term oral medical treatment, as an alternative to surgery, that safely and effectively manages heavy menstrual bleeding and improves leiomyoma-related symptoms and quality of life for women with symptomatic leiomyomas.

Elagolix is an oral, nonpeptide gonadotropin-releasing hormone antagonist that results in dose-dependent suppression of gonadotropins and ovarian sex hormones and is approved for the management of moderate-to-severe pain related to endometriosis. Here we report results from a phase 3 extension study (Elaris UF-EXTEND) that investigated the efficacy of elagolix 300 mg twice daily with hormonal add-back therapy (estradiol 1 mg and norethindrone acetate 0.5 mg once daily) in reducing heavy menstrual bleeding in women with uterine leiomyomas for up to 12 months of continuous treatment and the longer-term effects of this treatment on hypoestrogenic side effects (bone mineral density decrease and vasomotor symptoms).

ROLE OF THE FUNDING SOURCE {#s1}
==========================

AbbVie Inc, funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. The authors had access to relevant aggregated study data and other information (such as study protocol, analytic plan and report, validated data table, and clinical study report) required to understand and report research findings. The authors vouch for the presentation and publication of the research findings, have been fully involved at all stages of publication and presentation development, and are willing to take public responsibility for all aspects of the work. All individuals included as authors and contributors who made substantial intellectual contributions to the research, data analysis, and publication or presentation development are listed appropriately. The role of the sponsor in the design, execution, analysis, reporting, and funding is fully disclosed. The authors\' personal interests, financial or nonfinancial, relating to this research and its publication have been disclosed.

METHODS {#s2}
=======

Elaris UF-EXTEND was conducted at 115 sites in the United States (including Puerto Rico) and Canada from September 2016 to March 2019. This extension study enrolled women who completed 6 months of treatment in one of the two preceding, randomized, double-blind, placebo-controlled, 6-month phase 3 studies (Elaris UF-1 and UF-2). Women who received elagolix 300 mg twice daily with add-back therapy (estradiol 1 mg and norethindrone acetate 0.5 mg once daily) or elagolix 300 mg twice daily alone in UF-1 or UF-2 continued the same treatment for an additional 6 months in the UF-EXTEND extension study; women on placebo were randomized 1:1 to receive either elagolix with add-back therapy or elagolix alone for up to 6 months of treatment. All women were followed up to 12 months posttreatment. Study participants were provided with a known dose of elagolix; however, the elagolix with add-back dose was blinded. Study site personnel and participants remained blinded to each participant\'s original treatment from the preceding UF-1 and UF-2 trials and throughout this extension study. This study was approved by the institutional review board or ethics committee for each study site and was conducted in accordance with International Conference on Harmonisation guidelines and applicable regulations and ethical principles of the Declaration of Helsinki.

Here we report results from women who received up to an additional 6 months (12 continuous months total) of elagolix with add-back therapy or elagolix alone in UF-EXTEND; the elagolix alone arm was used to characterize the effect of add-back therapy on hypoestrogenic effects of elagolix. Results from women who received placebo in UF-1 or UF-2 and up to 6 months of elagolix treatment in UF-EXTEND are presented in Appendices 1--4, available online at <http://links.lww.com/AOG/B843>.

As previously described, up to 6 months of elagolix with add-back therapy achieved statistical significance compared with placebo (*P*\<.001) in reducing menstrual blood loss in women with heavy menstrual bleeding associated with uterine leiomyomas in both UF-1 and UF-2.^[@R17]^ In the present manuscript, data from UF-1 and UF-2 were pooled and presented side-by-side with the UF-EXTEND data to assess sustainability of elagolix effects across the 12-month treatment course.

Eligibility criteria for Elaris UF-1 and UF-2 have been previously described.^[@R17]^ Briefly, participants were premenopausal women between 18 and 51 years of age who had an ultrasound-confirmed diagnosis of uterine leiomyomas and heavy menstrual bleeding (more than 80 mL of menstrual blood loss per cycle as measured with alkaline hematin) at the time of screening. Women who completed the 6-month treatment period in UF-1 or UF-2 were eligible to enter UF-EXTEND if they had a bone mineral density decrease less than 8% in the spine, total hip, and femoral neck, had no clinically significant endometrial pathology on endometrial biopsy, and provided written, informed consent for extended treatment.

All women were instructed to use two forms of nonhormonal contraception (ie, condom with spermicide, diaphragm with spermicide, cervical cap with spermicide) consistently throughout UF-1 and -2 and UF-EXTEND; pregnancy tests were performed monthly at each study visit. In addition, women who were anemic (hemoglobin of less than 12 g/dL) at screening or during the studies were instructed to take iron supplements (300--325 mg of ferrous sulfate); the regimen was determined by the investigator.

All bleeding endpoints were assessed using the alkaline hematin method, which objectively quantifies the amount of blood in used sanitary products collected during the 6-month treatment period of UF-EXTEND and up through the first menses with full menstrual flow in the posttreatment follow-up period.^[@R17],[@R18]^ Women who did not return any used sanitary products at any visit during the treatment period or before the first menses in the posttreatment follow-up period were asked a standardized question to determine whether or not they had any menstrual bleeding or spotting since their previous study visit. If no bleeding was indicated over an interval, the menstrual blood loss over the interval was considered as zero.

As in UF-1 and UF-2, the primary efficacy endpoint of UF-EXTEND was the percentage of women who had less than 80 mL of menstrual blood loss during the final month and a 50% or greater reduction in menstrual blood loss from baseline to final month. Women who met these two criteria of the primary endpoint but prematurely discontinued study drug because of an adverse event, lack of efficacy, or required surgery or invasive intervention for treatment of uterine leiomyomas were categorized as not having met the primary endpoint. A sensitivity analysis of the primary endpoint was also performed without taking into account reasons for premature discontinuation of the study drug. Secondary efficacy endpoints included change and percent change from baseline in menstrual blood loss to each month and final month, percentage of women with suppression of bleeding (no bleeding, spotting allowed) at the final month, and percentage of women with baseline hemoglobin of 10.5 g/dL or less who had an increase in hemoglobin greater than 2 g/dL at month 6. Other efficacy endpoints included the percentage of women with amenorrhea at final month and control of bleeding (no bleeding, up to 1 day of spotting allowed) at final month and change from baseline in the Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire scores at month 6.^[@R17],[@R19]^

Average leiomyoma and uterine volume were assessed during UF-EXTEND treatment and posttreatment follow-up periods by pelvic ultrasonography (transabdominal and transvaginal) in all women and by magnetic resonance imaging (MRI) in a subset of women who elected to participate in additional imaging. Average leiomyoma volume was measured based on the average of up to three leiomyomas observed at the given time point. All imaging assessments were read centrally (Parexel International Corporation, Waltham, Massachusetts).

Adverse events were coded using the Medical Dictionary for Regulatory Activities 21.0 and categorized by severity (mild, moderate, or severe) by investigators. Adverse events with new onset (or changed severity) on or after the first dose date and within 30 days after the last dose date were considered treatment-emergent. Serious adverse events were those that were life-threatening, required hospitalization or prolongation of hospitalization, required medical or surgical intervention to prevent serious outcome, or resulted in persistent or significant disability or death. Hot flushes and night sweats were also self-reported at scheduled visits by women in a supplemental questionnaire; women who reported an adverse event of hot flush or night sweats were asked the number and severity of either or both hot flushes and night sweats they experienced over the previous 24 hours at each visit thereafter until resolution of the adverse event.

Bone mineral density in the lumbar spine, total hip, and femoral neck were assessed by dual-energy X-ray absorptiometry scans (GE-Lunar, Madison, Wisconsin; Hologic, Marlborough, Massachusetts), which were performed every 6 months during the treatment and posttreatment follow-up periods of this extension study, and were read centrally (Parexel International Corporation, Waltham, Massachusetts). Clinical laboratory tests, including hemoglobin, lipid panel, and liver function tests, were performed during the screening period of the preceding UF-1 and UF-2 studies, at baseline and each treatment month (or at premature discontinuation), and at applicable posttreatment follow-up visits, and were read centrally (Q2 Solutions, Valencia, California). Endometrial biopsies were performed during screening and at month 6 (or at premature discontinuation) and read centrally (Q2 Solutions).

Approximately 400 women were expected to enroll in the Elaris UF-EXTEND study based on estimated rollover and discontinuation rates in Elaris UF-1 and UF-2. All efficacy and safety analyses included all women who received at least one dose of the study drug in this extension study, including those who prematurely discontinued the study drug or withdrew consent. Baseline values for all measures were defined as before dosing in either UF-1 and UF-2 for women who received elagolix treatment in those studies (for women who received placebo in UF-1 or UF-2, baseline was defined as the last value before the first dose of elagolix in UF-EXTEND, unless otherwise specified). Final month was defined as the last 28 days before and including the last dose date in UF-EXTEND.

Statistical comparisons between the elagolix with add-back therapy and elagolix-alone groups that received up to 12 months of treatment were not prespecified and therefore were not performed in UF-EXTEND, as the study was not designed for these analyses, except when evaluating changes in bone mineral density. The primary endpoint and secondary endpoints of categorical assessments (eg, percentage of women with suppression of bleeding at the final month and percentage of women with baseline hemoglobin of 10.5 g/dL or less who had an increase in hemoglobin greater than 2 g/dL at month 6) were summarized by frequency and percentages. The secondary endpoints of all change and percent change from baseline analyses were summarized with descriptive statistics. Statistical testing was only performed for percent changes in bone mineral density using SAS 9.4 with an analysis of covariance model with treatment as the main effect and baseline value as a covariate with a two-sided significance level of 0.05 and a 95% CI.

RESULTS {#s3}
=======

A total of 433 women who completed the 6-month treatment period in Elaris UF-1 or UF-2 were enrolled and treated in Elaris UF-EXTEND (Fig. [1](#F1){ref-type="fig"}). Of these women, 218 were treated with elagolix plus add-back therapy (98 with elagolix alone) in the preceding studies and continued the same treatment for up to an additional 6 months in UF-EXTEND; thus, were included in this analysis. Similar proportions of women in each treatment group (16.5% for elagolix with add-back therapy and 19.4% for elagolix alone) discontinued the study drug, with the most common primary reason for discontinuation being lost to follow-up (5.0% and 5.1% respectively). As summarized in Table [1](#T1){ref-type="table"}, the demographics and baseline characteristics of women enrolled in UF-EXTEND were generally well-balanced across the treatment groups and similar to those of the overall population of UF-1 and UF-2.

![Study design and disposition of women treated with up to 12 months of elagolix. Elagolix alone, elagolix 300 mg twice daily throughout UF-1 and UF-2 and UF-EXTEND; elagolix with add-back therapy, elagolix 300 mg twice daily with add-back therapy (estradiol 1 mg and norethindrone 0.5 mg once daily) throughout UF-1 and UF-2 and UF-EXTEND. \*In UF-1 and UF-2 combined, 5 of 150 (3.3%) women treated with elagolix alone and 3 of 312 (1.0%) women treated with elagolix plus add-back therapy did not enter UF-EXTEND because of a dual-energy X-ray absorptiometry scan (DXA) finding of bone mineral density decrease greater than 8% in at least one of the anatomic locations (lumbar spine, total hip, and femoral neck). ^†^The most common other reason was that the extension study was closed to enrollment. ^‡^Women required surgery or invasive intervention for treatment of uterine leiomyomas. Other reasons for premature discontinuation included moved out of state (n=2), weight exceeded DXA limits, study site closing, participant stopped drug because she thought she was pregnant but was not, did not like bleeding while on medication, personal reasons, and DXA results.\
Simon. Twelve Months of Elagolix With Add-Back Therapy. Obstet Gynecol 2020.](ong-135-1313-g001){#F1}

###### 

Patient Demographics and Baseline Characteristics in Women Treated With Up to 12 Months of Elagolix\*

![](ong-135-1313-g002)

Of the women who received up to 12 months of elagolix with add-back therapy in Elaris UF-EXTEND, the proportion who met the two bleeding criteria of the primary endpoint was 87.9% (95% CI \[83.4--92.3\], n=206) and 89.4% (95% CI \[83.1--95.6\], n=94) for elagolix alone; Appendix 5, available online at <http://links.lww.com/AOG/B843>); these results were consistent with the results pooled from UF-1 and UF-2 {72.2% (95% CI \[67.7--76.7\]) for elagolix with add-back therapy and 80.6% (95% CI \[74.9--86.2\]) for elagolix alone} (Fig. [2](#F2){ref-type="fig"}A; Appendix 5 \[<http://links.lww.com/AOG/B843>\]). The results of a sensitivity analysis of the primary endpoint which did not consider reasons for premature discontinuation of the study drug were similar to those of the primary analysis (Appendix 6, available online at <http://links.lww.com/AOG/B843>). Results of the primary endpoint from women who received placebo in either UF-1 or UF-2 and up to 6 months of elagolix treatment in UF-EXTEND are presented in Appendix 3 (<http://links.lww.com/AOG/B843>).

![Percentage of women who met the primary endpoint (**A**) and mean change from baseline in menstrual blood loss in women treated with up to 12 months of elagolix with add-back therapy (**B**). Data are % or mean with *error bars* indicating 95% CI. Baseline was before first dosing in the UF-1 and UF-2 studies. \*Mean changes from baseline in menstrual blood loss for UF-1 and UF-2 are presented as least squares means.\
Simon. Twelve Months of Elagolix With Add-Back Therapy. Obstet Gynecol 2020.](ong-135-1313-g003){#F2}

Mean reductions in menstrual blood loss seen at month 6 of UF-1 and UF-2 were sustained through an additional 6 months of elagolix with add-back therapy during UF-EXTEND; mean changes from baseline ranged from −186.5 mL (95% CI \[−209.2 to −163.9\]) at extension month 1 to −211.4 mL (95% CI \[−239.1 to −183.7\]) at extension month 6 (Fig. [2](#F2){ref-type="fig"}B; mean percent change in Appendix 7, available online at <http://links.lww.com/AOG/B843>). The majority of women receiving elagolix with add-back therapy achieved suppression of bleeding {74.8% (95% CI \[68.8--80.7\])} at the final month of UF-EXTEND; the corresponding percentage at the final month of UF-1 and UF-2 combined was 58.9% (95% CI \[53.8--64.0\]) (Table [2](#T2){ref-type="table"}). Additionally, the majority of women receiving elagolix with add-back therapy who had a low baseline hemoglobin level of 10.5 g/dL or less showed an increase from baseline greater than 2 g/dL at UF-EXTEND month 6 (72.5%, 95% CI \[60.3--84.8\]); the corresponding percentage at month 6 of UF-1 and UF-2 combined was 56.0% (95% CI \[46.3--65.7\]) (Table [2](#T2){ref-type="table"}). Results of secondary and other efficacy endpoints from women who received elagolix alone up to 12 months are presented in Appendix 5 (<http://links.lww.com/AOG/B843>) and in Appendix 3 (<http://links.lww.com/AOG/B843>) for women who received placebo in UF-1 or UF-2 and up to 6 months of elagolix treatment in UF-EXTEND.

###### 

Secondary and Other Efficacy Endpoints After 6 Months and 12 Months of Elagolix Treatment in Women Treated With Up to 12 months of Elagolix\*

![](ong-135-1313-g004)

More than half of the women who received up to 12 months of elagolix with add-back therapy achieved amenorrhea (64.6%, 95% CI \[58.0--71.1\]) and control of bleeding (64.6%, 95% CI \[58.0--71.1\]) at the final month of UF-EXTEND, respectively. In the elagolix with add-back group, there was a small increase in mean average leiomyoma volume from baseline to UF-EXTEND month 6 (1.5 cm^3^ \[95% CI −6.0 to 8.9\] measured by ultrasound scan and 9.4 cm^3^ \[95% CI −1.2 to 20.0\] by MRI); however, mean uterine volume was reduced at UF-EXTEND month 6 {−57.3 cm^3^ (95% CI \[−85.0 to −29.5\]) by ultrasound scan and −30.0 cm^3^ (95% CI \[−65.8 to 5.8\]) by MRI} (Appendix 8, available online at <http://links.lww.com/AOG/B843>). Elagolix with add-back treatment was also associated with improved quality of life based on mean changes from baseline to UF-EXTEND month 6 in Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire scores, including symptom severity score and total HRQL score (subscales included Concern, Activities, Energy and mood, Control, Self-conscious, Sexual function) (Appendix 9, available online at <http://links.lww.com/AOG/B843>).

Furthermore, of the women who received up to an additional 6 months of elagolix with add-back therapy during UF-EXTEND and entered the posttreatment follow-up period (n=184), the majority of these women (79.3%) reported a first posttreatment menses within 2 months after stopping the study drug; mean volume of the first posttreatment menses was 198.7 mL.

Approximately 60% of women who received up to 12 months of elagolix with add-back therapy or elagolix alone had at least one treatment-emergent adverse event with an onset on or after the first dose of study drug in this extension study (Table [3](#T3){ref-type="table"}). The most frequently reported adverse events with elagolix plus add-back therapy were hot flush and headache; which are consistent with those of UF-1 and UF-2. The most common adverse events leading to treatment discontinuation during the second 6 months of treatment were bone density decrease (elagolix alone: four \[4.1%\]; elagolix with add-back therapy: one \[0.5%\]) and depression (elagolix alone: one \[1.0%\]; elagolix with add-back therapy: one \[0.5%\]). The majority of adverse events were considered nonserious and mild or moderate in severity by investigators. Serious adverse events that led to study drug discontinuation included breast cancer (n=1), menorrhagia and pelvic pain (n=1), and hysterectomy (n=1); all of which occurred in the elagolix with add-back group. The profile of adverse events from women who received placebo in UF-1 or UF-2 and up to 6 months of elagolix treatment in UF-EXTEND are presented in Appendix 4 (<http://links.lww.com/AOG/B843>). The rate of adverse events over the course of 12 months of elagolix treatment are listed in Appendix 10, available online at <http://links.lww.com/AOG/B843>.

###### 

Overview of Treatment-Emergent Adverse Events During UF-EXTEND for Women Who Received Up to 12 Months of Elagolix\*

![](ong-135-1313-g005)

There was one pregnancy that was reported during the treatment period of UF-EXTEND; a woman had a positive urine pregnancy test confirmed by a positive serum pregnancy test on day 90, discontinued the study drug the same day, and had a spontaneous abortion on day 95 (Posttreatment day 6). No deaths were reported in the elagolix treatment groups during the extension study.

Among women who received up to 12 months of elagolix treatment, the overall rate of either or both hot flushes and night sweats with new onset in this extension study were reported by 7.8% of women in the elagolix with add-back group and 5.1% in the elagolix-alone group; none of these women discontinued the study drug because of either or both hot flush and night sweat events, as none of the events were considered serious by investigators. Based on a supplemental form completed by the women themselves, fewer women in the elagolix with add-back group (range, n = 19--29) reported either or both hot flush and night sweats every month during the treatment period even though the elagolix with add-back group had approximately twice as many women as the elagolix-alone group (range, n =37--49, Appendix 11, available online at <http://links.lww.com/AOG/B843>). Participant-reported supplemental form data also showed that a smaller percentage of women in the elagolix with add-back group than in the elagolix-alone group had a maximal severity of moderate or severe for either or both hot flush and night sweat events at most treatment months. The mean number of these events were lower in the elagolix with add-back group than in the elagolix-alone group at most months (Appendix 12, available online at <http://links.lww.com/AOG/B843>).

The lumbar spine mean bone mineral density percent change from baseline for the elagolix alone treatment group was −4.8% (95% CI \[−5.4 to −4.1\]; median Z-score 0.5) and for elagolix with add-back therapy −1.5% (95% CI \[−1.9 to −1.0\]; median Z-score 0.8) in women who received up to 12 months of treatment at UF-EXTEND month 6 (Fig. [3](#F3){ref-type="fig"}). At the same anatomical location, at posttreatment month 6 the mean bone mineral density percent change from baseline for the elagolix alone treatment group was −2.8% (95% CI \[−3.6 to −1.9\]; median Z-score 0.5) and for elagolix with add-back therapy −0.6% (95% CI \[−1.1 to −0.1\]; median Z-score 1.0), and at posttreatment Month 12, −2.0% (95% CI \[−2.8 to −1.2\]; median Z-score 0.6), and −0.6% (95% CI \[−1.1 to −0.0\]; median Z-score 1.1), respectively. Similar trends were seen at the total hip and femoral neck locations (Figs. [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}).

![Lumbar spine bone mineral density changes from baseline (**A**) and bone mineral density Z-scores during treatment and posttreatment periods in women treated with up to 12 months of elagolix (**B**). Bone mineral density changes are presented as least square mean percent change, with *error bars* indicating 95% CI. Bone mineral density Z-scores are presented as median, quartile 1, quartile 3, and range. Bone mineral density changes and Z-scores for UF-1 and UF-2 exclude participants who switched machine types. Elagolix alone, elagolix 300 mg twice daily throughout UF-1 and UF-2 and UF-EXTEND; elagolix with add-back therapy, elagolix 300 mg twice daily with add-back therapy (estradiol 1 mg and norethindrone 0.5 mg once daily) throughout UF-1 and UF-2 and UF-EXTEND. Baseline was before first dosing in UF-1 and UF-2 studies. \**P*≤.05 for test of difference between the elagolix with add-back therapy and elagolix-alone groups using an analysis of covariance model with treatment as the main effect and baseline value as a covariate for extension month 6.\
Simon. Twelve Months of Elagolix With Add-Back Therapy. Obstet Gynecol 2020.](ong-135-1313-g006){#F3}

![Total hip bone mineral density changes from baseline (**A**) and bone mineral density Z-scores during treatment and posttreatment periods in women treated with up to 12 months of elagolix (**B**). Bone mineral density changes are presented as least square mean percent change with *error bars* indicating 95% CI. Bone mineral density Z-scores are presented as median, quartile 1, quartile 3, and range. Bone mineral density changes and Z-scores for UF-1 and UF-2 exclude participants who switched machine types. Elagolix alone, elagolix 300 mg twice daily throughout UF-1 and UF-2 and UF-EXTEND; elagolix with add-back therapy, elagolix 300 mg twice daily with add-back therapy (estradiol 1 mg and norethindrone 0.5 mg once daily) throughout UF-1 and UF-2 and UF-EXTEND. Baseline was before first dosing in UF-1 and UF-2 studies. \**P*≤.05 for test of difference between the elagolix with add-back therapy and elagolix-alone groups using an analysis of covariance model with treatment as the main effect and baseline value as a covariate for extension month 6.\
Simon. Twelve Months of Elagolix With Add-Back Therapy. Obstet Gynecol 2020.](ong-135-1313-g007){#F4}

![Femoral neck bone mineral density changes from baseline (**A**) and bone mineral density Z-scores during treatment and posttreatment periods in women treated with up to 12 months of elagolix (**B**). Bone mineral density changes are presented as least square mean percent change, with *error bars* indicating 95% CI. Bone mineral density Z-scores are presented as median, quartile 1, quartile 3, and range. Bone mineral density changes and Z-scores for UF-1 and UF-2 exclude participants who switched machine types. Elagolix alone, elagolix 300 mg twice daily throughout UF-1 and UF-2 and UF-EXTEND; elagolix with add-back therapy, elagolix 300 mg twice daily with add-back therapy (estradiol 1 mg and norethindrone 0.5 mg once daily) throughout UF-1 and UF-2 and UF-EXTEND. Baseline was before first dosing in UF-1 and UF-2 studies. \**P*≤.05 for test of difference between the elagolix with add-back therapy and elagolix-alone groups using an analysis of covariance model with treatment as the main effect and baseline value as a covariate for extension month 6.\
Simon. Twelve Months of Elagolix With Add-Back Therapy. Obstet Gynecol 2020.](ong-135-1313-g008){#F5}

Bone mineral density changes from baseline were less with elagolix with add-back therapy compared with elagolix alone; the differences between groups were statistically significant. For all locations, a higher percentage of women in the elagolix with add-back group than in the elagolix-alone group had an increase or no change in bone mineral density from baseline to UF-EXTEND month 6. A smaller percentage of women in the elagolix with add-back group than in the elagolix-alone group had more than 3% bone mineral density decreases at UF-EXTEND month 6 (Appendix 13, available online at <http://links.lww.com/AOG/B843>). Thirty women treated with elagolix for up to 12 months (23 in the elagolix-alone group and seven in the elagolix with add-back group) had an 8% or greater bone mineral density decrease at one or more anatomic locations during the 6 months of UF-EXTEND, of whom five (four in the elagolix-alone group and one in the elagolix with add-back group) had a Z-score of −1.5 or less in the same location where they had the 8% or greater bone mineral density decrease. None of these 30 women had bone fractures. At UF-EXTEND posttreatment months 6 and 12 for all anatomical locations, no women at any anatomical location had a Z-score less than −2.0, the lower bound of the normal age- and race-matched range (Figs. [3](#F3){ref-type="fig"}--[5](#F5){ref-type="fig"}).^[@R20]^

Women who received up to 12 months of elagolix treatment had transient elevations in low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B that generally occurred within the first 3 months of treatment during UF-1 and UF-2 and then stabilized. The mean increases in these serum lipid levels were lower with elagolix plus add-back therapy than with elagolix alone (Appendix 14, available online at <http://links.lww.com/AOG/B843>). In the elagolix with add-back group, both mean LDL-C and apolipoprotein B levels returned to near baseline levels by posttreatment follow-up month 3. Mean triglyceride levels were generally similar to baseline in the elagolix with add-back group and were lower than in the elagolix-alone group.

None of the women discontinued the study drug because of an adverse event of anemia. In women receiving up to 12 months of elagolix, treatment led to increases in mean hemoglobin levels from baseline (Appendix 15, available online at <http://links.lww.com/AOG/B843>).

Two women who received up to 12 months of elagolix treatment (one in the elagolix with add-back group and one in the elagolix-alone group) had elevations in liver transaminase levels during UF-EXTEND that were more than three times or more than five times the upper limit normal; neither had concurrent elevations in bilirubin and no pattern in time to onset was identified. In both of these women, their elevations were asymptomatic and declined within 1--4 months after peak values, regardless of study drug continuation. Of these two women, only the one in the elagolix-alone group discontinued the study drug because of liver transaminase elevations; her levels returned to normal after the study drug was discontinued. Further, there were no cases of severe liver injury (ie, irreversible liver failure that is fatal or requires liver transplantation) reported in UF-EXTEND, and no one met the biochemical criteria for Hy's law.

Results from the endometrial biopsy showed no evidence of hyperplasia or malignancy at baseline or UF-EXTEND month 6 and no treatment-emergent adverse event of ovarian cysts were reported during the extension study. Despite cycle-related differences, mean endometrial thickness, as measured by ultrasound scan or MRI, decreased from baseline to UF-EXTEND month 6 in each of the two elagolix groups that received up to 12 months of treatment (Appendix 16, available online at <http://links.lww.com/AOG/B843>).

DISCUSSION {#s4}
==========

Previous reports of two phase 3 studies (Elaris UF-1 and UF-2) showed that up to 6 months of elagolix 300 mg twice daily with hormonal add-back therapy (1 mg estradiol and 0.5 mg norethindrone acetate once daily), when compared with placebo, significantly reduced menstrual bleeding and improved quality of life in women with heavy menstrual bleeding associated with uterine leiomyomas. Herein, this corresponding extension study demonstrated maintenance of these effects for an additional 6 months (up to 12 months total) of elagolix with add-back treatment. In women who received up to 12 months of elagolix with add-back therapy, the majority of women (87.9%) met the primary endpoint of having both less than 80 mL of menstrual blood loss at the final month and a 50% or greater reduction in menstrual blood loss from baseline to final month. Reductions in menstrual blood loss were consistent across the 12-month treatment course. Similar to the results of the preceding UF-1 and UF-2 studies, most women treated with elagolix with add-back therapy achieved suppression of bleeding (74.8%) at the final month in UF-EXTEND and, among those with baseline hemoglobin of 10.5 g/dL or less, had an increase of more than 2 g/dL in hemoglobin after 12 months of treatment (72.5%).

Safety findings in Elaris UF-EXTEND were also consistent with those previously reported in the preceding 6 months UF-1 and UF-2 studies; the inclusion of add-back therapy attenuated hypoestrogenic side effects associated with the use of elagolix alone, including hot flushes, night sweats, and bone mineral density decreases. There were minimal new cases of either or both hot flushes and night sweats in UF-EXTEND. As expected, elagolix with add-back therapy was associated with numerically lower incidence and reduced severity of either or both hot flushes and night sweats throughout the treatment period based on patient-reported supplemental form data.

The effect of add-back therapy on attenuating bone mineral density changes, as seen with the initial 6 months of treatment in UF-1 and UF-2, were maintained with up to an additional 6 months of treatment in UF-EXTEND, mean percent bone mineral density changes were statistically significantly less with elagolix plus add-back therapy than with elagolix alone. Furthermore, a greater proportion of women in the elagolix with add-back group than in the elagolix-alone group had a numerical increase or no change in bone mineral density. For women who had a numerical decrease in bone mineral density with up to 12 months of elagolix plus add-back therapy, most were in a category of less than 5% for lumbar spine.

Elagolix with add-back therapy was associated with transient lipid elevations in LDL-C and apolipoprotein B that were first observed during the first 3 months of treatment in UF-1 and UF-2 and then remained stable; an additional 6 months of treatment in UF-EXTEND did not further increase the lipid levels. The mechanism for these changes is not known, but in most cases increases in concentrations of apoB-containing lipoproteins are explained by a reduction in LDL receptor-mediated clearance often related to decreased receptor expression or function.^[@R21],[@R22]^ After study drug discontinuation, lipid levels usually returned to pretreatment levels by month 3 of the posttreatment follow-up period.

There were some methodologic limitations inherent to UF-EXTEND. For example, women were required to complete one of the preceding UF-1 or UF-2 phase 3 studies to enroll in this extension study, resulting in a potential selection bias for women who responded to treatment. The absence of a placebo control in UF-EXTEND also limits the interpretation of the results. Despite these factors, the treatment length is a strength of the extension study, as the safety (including bone mineral density and other hypoestrogenic effects) and efficacy of elagolix with add-back therapy were evaluated for up to 12 months of treatment, and bone mineral density recovery for up to 12 months posttreatment. An additional strength is the inclusion of the elagolix alone reference arm, which was used to characterize the effects of add-back therapy on the hypoestrogenic effects of elagolix. The objective measurement of menstrual blood loss using the alkaline hematin method also adds credibility to the study as other methods, such as the pictorial blood loss assessment chart and bleeding journals, are semiquantitative and subjective.^[@R23]--[@R25]^
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